MLKL and neoplasm: Emodin significantly reduced tumor growth promoting necroptosis, as demonstrated by the increased levels of TNF-α (tumor necrosis factor α), RIP1, RIP3, and MLKL (mixed lineage kinase domain-like protein) observed in tumor tissues of the emodin-treated group [77].